Why the study?
Recent insights into diagnosis, steroid treatment, rehabilitation, systemic care, and new drug approvals created a need to update previous care recommendations for Brazilian patients with Duchenne muscular dystrophy.
Answers are grounded in this paper and cite their sources.
This document provides an updated, evidence-based consensus on the standard of care for Brazilian patients with Duchenne muscular dystrophy.
In the last few decades, there have been considerable improvements in the diagnosis and care of Duchenne muscular dystrophy (DMD), the most common childhood muscular dystrophy. International guidelines have been published and recently reviewed. A group of Brazilian experts has developed a standard of care based on a literature review with evidence-based graded recommendations in a two-part publication. Implementing best practice management has helped change the natural history of this chronic progressive disorder, in which the life expectancy for children of the male sex in the past used to be very limited. Since the previous publication, diagnosis, steroid treatment, rehabilitation, and systemic care have gained more significant insights with new original work in certain fields. Furthermore, the development of new drugs is ongoing, and some interventions have been approved for use in certain countries. Therefore, we have identified the need to review the previous care recommendations for Brazilian patients with DMD. Our objective was to create an evidence-based document that is an update on our previous consensus on those topics.
No takes yet. Share an insight, caveat, or question.
Araújo et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: